Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma
This study has been withdrawn prior to enrollment.
(Principal Investigator left institution.)
Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
Merck
Information provided by (Responsible Party):
The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
NCT01296659
First received: February 3, 2011
Last updated: July 11, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Ridaforolimus has been tested in almost 2 dozen studies; however, it has not previously been tested in combination with the standard of care chemotherapy for sarcoma as this study will. We will be looking to see if Ridaforolimus given with SOC chemo (AIM or TG) is well tolerated and to determine a Phase 2 dose.
| Condition | Intervention | Phase |
|---|---|---|
|
Soft Tissue Sarcoma |
Drug: ridaforolimus |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase Ib Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Patients With Advanced Unresectable Soft Tissue Sarcoma |
Resource links provided by NLM:
Further study details as provided by The University of Texas Health Science Center at San Antonio:
Primary Outcome Measures:
- Define maximum tolerated dose (MTD) [ Time Frame: 12-18 months ] [ Designated as safety issue: Yes ]Defining the maximum tolerated dose (MTD) and recommended Phase II dose for the combination ridaforolimus and SOC chemotherapy
Secondary Outcome Measures:
- Number of Grade 2 or higher side effects with the combined therapy. [ Time Frame: 12-18 months ] [ Designated as safety issue: No ]Any evidence of antitumor activity--as measured by response rate (RECIST).
- Pharmacokinetics [ Time Frame: 12-18 months ] [ Designated as safety issue: Yes ]Ridaforolimus pharmacokinetics when given in combination with SOC chemotherapy. Limited PK for SOC chemotherapy when combined with ridaforlimus. We will measure change in concentration of Ridaforolimus when combined with chemotherapy.
| Enrollment: | 0 |
| Study Start Date: | February 2011 |
| Study Completion Date: | August 2011 |
| Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: AIM Arm
Ridaforolimus combined with doxorubicin/ifosfamide/mesma (AIM)
|
Drug: ridaforolimus
Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
Other Name: deforolimus
|
|
Experimental: TG Arm
Ridaforolimus combined with docetaxel and gemcitabine (TG)
|
Drug: ridaforolimus
Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
Other Name: deforolimus
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Advanced or metastatic soft tissue sarcoma with histological or cytological proven disease. No more than 2 lines of chemotherapy in the metastatic setting in the dose escalation phase, and no more than one line of prior therapy in the expansion phase.
- ECOG performance status of ≤ 1
- A minimum life expectancy > 3 months
- At least 4 weeks must have elapsed between prior investigational therapy, chemotherapy or radiotherapy and the first dose of ridaforolimus
- Adequate hematological, hepatic and renal function (hemoglobin ≥ 9g/dl, absolute neutrophil count [ANC] ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L; bilirubin ≤ ULN; alkaline phosphatase ≤ 2.5 x ULN; AST, ALT ≤ 2.5 x ULN; albumin ≥ 2.5mg/dL; creatinine ≤ 1.5 x ULN)
- Serum cholesterol ≤ 350 mg/dL and triglycerides ≤400 mg/dL
- Signed informed consent
- Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to start of therapy and must use an approved contraceptive method as appropriate from the time of screening until 30 days after the last dose of study drug.
Exclusion Criteria:
- Uncontrolled brain metastases, spinal cord compression, or carcinomatous meningitis.
- Clinically significant unexplained bleeding within 28 days prior to entering the trial
- Uncontrolled systemic vascular hypertension
- Clinically significant cardiovascular disease
- Newly diagnosed (within 3 months of enrollment) or poorly controlled type 1 or 2 diabetes
- Have received >350 mg/m2 total dose of Doxorubicin
- Active infection requiring prescribed intervention
- Other concurrent illness
- Major surgery within 28 days before trial entry, or incompletely healed surgical incision; minor surgery or procedures within 7 days
- Previous anthracycline lifetime exposure more than 350 mg/m2 would exclude patient form AIM Arm enrollment
- Pregnant or breastfeeding
- Known allergy to macrolide antibiotics
- Concurrent treatment with medications that induce or inhibit cytochrome P450 (CYP3A).
- Known history of HIV sero-positivity
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01296659
Locations
| United States, Texas | |
| Cancer Therapy & Research Center at UTHSCSA | |
| San Antonio, Texas, United States, 78229 | |
Sponsors and Collaborators
The University of Texas Health Science Center at San Antonio
Merck
Investigators
| Principal Investigator: | Monica Mita, MD | The University of Texas Health Science Center at San Antonio |
More Information
Additional Information:
No publications provided
| Responsible Party: | The University of Texas Health Science Center at San Antonio |
| ClinicalTrials.gov Identifier: | NCT01296659 History of Changes |
| Other Study ID Numbers: | IDD 10-09 |
| Study First Received: | February 3, 2011 |
| Last Updated: | July 11, 2012 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by The University of Texas Health Science Center at San Antonio:
|
sarcoma Ridaforolimus soft tissue sarcoma unresectable sarcoma |
Additional relevant MeSH terms:
|
Sarcoma Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Sirolimus Antibiotics, Antineoplastic Antineoplastic Agents Therapeutic Uses |
Pharmacologic Actions Antifungal Agents Anti-Infective Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Anti-Bacterial Agents |
ClinicalTrials.gov processed this record on May 19, 2013